NCT00754923View on ClinicalTrials.gov

Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Lung Cancer
Interventions
DRUG

sorafenib

administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient.

Trial Locations (1)

43210-1240

Ohio State University, Columbus

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT00754923 - Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter